{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T01:00:50Z","timestamp":1794013250068,"version":"4.8.0"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T00:00:00Z","timestamp":1661126400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/ http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:p>\n                    Up to 40% of pheochromocytomas (PCCs) and paragangliomas (PGLs) are hereditary. Germline mutations\/deletions in\n                    <jats:italic toggle=\"yes\">fumarate hydratase<\/jats:italic>\n                    (\n                    <jats:italic toggle=\"yes\">FH<\/jats:italic>\n                    ) cause hereditary leiomyomatosis and renal cell carcinoma syndrome which manifests predominantly with FH-deficient uterine\/cutaneous leiomyomas and renal cell carcinomas (RCCs)\u2014tumors characterized by loss of immunohistochemical (IHC) expression of FH and\/or positive staining for S-(2-succino)-cysteine. Occasional patients develop PCC\/PGL. We investigated the incidence, morphologic, and clinical features of FH-deficient PCC\/PGL. We identified 589 patients with PCC\/PGLs that underwent IHC screening for FH and\/or S-(2-succino)-cysteine. Eight (1.4%) PCC\/PGLs were FH deficient (1.1% in an unselected population). The median age for FH-deficient cases was 55 (range: 30 to 77\u00a0y) with 50% arising in the adrenal. All 4 with biochemical data were noradrenergic. Two (25%) metastasized, 1 dying of disease after 174 months. Germline testing was performed on 7 patients, 6 of whom had\n                    <jats:italic toggle=\"yes\">FH<\/jats:italic>\n                    missense mutations. None were known to have a significant family history before presentation or developed cutaneous leiomyomas, or FH-deficient RCC at extended follow-up. The patient wild-type for\n                    <jats:italic toggle=\"yes\">FH<\/jats:italic>\n                    on germline testing was demonstrated to have somatic\n                    <jats:italic toggle=\"yes\">FH<\/jats:italic>\n                    mutation and loss of heterozygosity corresponding to areas of subclonal FH deficiency in her tumor. One patient did not undergo germline testing, but\n                    <jats:italic toggle=\"yes\">FH<\/jats:italic>\n                    mutation was demonstrated in his tumor. We conclude that FH-deficient PCC\/PGL are underrecognized but can be identified by IHC. FH-deficient PCC\/PGL are strongly associated with germline missense mutations but are infrequently associated with leiomyoma or RCC, suggesting there may be a genotype-phenotype correlation. FH-deficient PCC\/PGL may have a higher metastatic risk.\n                  <\/jats:p>","DOI":"10.1097\/pas.0000000000001945","type":"journal-article","created":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T09:00:11Z","timestamp":1661158811000},"page":"25-36","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":22,"title":["A Clinicopathologic and Molecular Analysis of Fumarate Hydratase\u2013deficient Pheochromocytoma and Paraganglioma"],"prefix":"10.1097","volume":"47","author":[{"given":"Talia L.","family":"Fuchs","sequence":"first","affiliation":[{"name":"Cancer Diagnosis and Pathology Group"},{"name":"Sydney Medical School, University of Sydney, Sydney"},{"name":"Douglass Hanly Moir Pathology, Macquarie Park, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Luxford","sequence":"additional","affiliation":[{"name":"Cancer Genetics Laboratory, Kolling Institute of Medical Research, Royal North Shore Hospital"},{"name":"Sydney Medical School, University of Sydney, Sydney"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adele","family":"Clarkson","sequence":"additional","affiliation":[{"name":"Cancer Diagnosis and Pathology Group"},{"name":"Department of Anatomical Pathology, NSW Health Pathology, Royal North Shore Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Sheen","sequence":"additional","affiliation":[{"name":"Cancer Diagnosis and Pathology Group"},{"name":"Department of Anatomical Pathology, NSW Health Pathology, Royal North Shore Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loretta","family":"Sioson","sequence":"additional","affiliation":[{"name":"Cancer Diagnosis and Pathology Group"},{"name":"Department of Anatomical Pathology, NSW Health Pathology, Royal North Shore Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Elston","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Waikato Hospital, Hamilton"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Croxson","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Auckland District Health Board, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trisha","family":"Dwight","sequence":"additional","affiliation":[{"name":"Cancer Genetics Laboratory, Kolling Institute of Medical Research, Royal North Shore Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana E.","family":"Benn","sequence":"additional","affiliation":[{"name":"Cancer Genetics Laboratory, Kolling Institute of Medical Research, Royal North Shore Hospital"},{"name":"Sydney Medical School, University of Sydney, Sydney"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyndal","family":"Tacon","sequence":"additional","affiliation":[{"name":"Cancer Genetics Laboratory, Kolling Institute of Medical Research, Royal North Shore Hospital"},{"name":"Department of Endocrinology, Royal North Shore Hospital"},{"name":"Sydney Medical School, University of Sydney, Sydney"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Field","sequence":"additional","affiliation":[{"name":"Department of Cancer Services, Northern Sydney Local Health District Familial, Cancer Service, Royal North Shore Hospital, St Leonards, Sydney"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahsa S.","family":"Ahadi","sequence":"additional","affiliation":[{"name":"Cancer Diagnosis and Pathology Group"},{"name":"Department of Anatomical Pathology, NSW Health Pathology, Royal North Shore Hospital"},{"name":"Sydney Medical School, University of Sydney, Sydney"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Chou","sequence":"additional","affiliation":[{"name":"Cancer Diagnosis and Pathology Group"},{"name":"Department of Anatomical Pathology, NSW Health Pathology, Royal North Shore Hospital"},{"name":"Sydney Medical School, University of Sydney, Sydney"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roderick J.","family":"Clifton-Bligh","sequence":"additional","affiliation":[{"name":"Cancer Genetics Laboratory, Kolling Institute of Medical Research, Royal North Shore Hospital"},{"name":"Department of Endocrinology, Royal North Shore Hospital"},{"name":"Sydney Medical School, University of Sydney, Sydney"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J.","family":"Gill","sequence":"additional","affiliation":[{"name":"Cancer Diagnosis and Pathology Group"},{"name":"Department of Anatomical Pathology, NSW Health Pathology, Royal North Shore Hospital"},{"name":"Sydney Medical School, University of Sydney, Sydney"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,8,22]]},"reference":[{"key":"R1-20250608","first-page":"802","article-title":"Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979","volume":"58","author":"Beard","year":"1983","journal-title":"Mayo Clin Proc"},{"key":"R2-20250608","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/MPA.0b013e3181ebb4f0","article-title":"The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer","volume":"39","author":"Chen","year":"2010","journal-title":"Pancreas"},{"key":"R3-20250608","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/his.13402","article-title":"Pathology and genetics of phaeochromocytoma and paraganglioma","volume":"72","author":"Turchini","year":"2018","journal-title":"Histopathology"},{"key":"R4-20250608","first-page":"354","article-title":"Prevalence of clinically unsuspected pheochromocytoma. Review of a 50-year autopsy series","volume":"56","author":"Sutton","year":"1981","journal-title":"Mayo Clin Proc"},{"key":"R6-20250608","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ccell.2017.01.009","article-title":"Pheochromocytomas and paragangliomas, genetically diverse and minimalist, all at once!","volume":"31","author":"Dahia","year":"2017","journal-title":"Cancer Cell"},{"key":"R7-20250608","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s12022-020-09658-7","article-title":"What have we learned from molecular biology of paragangliomas and pheochromocytomas?","volume":"32","author":"Papathomas","year":"2021","journal-title":"Endocr Pathol"},{"key":"R8-20250608","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3390\/cancers14030594","article-title":"New insights on the genetics of pheochromocytoma and paraganglioma and its clinical implications","volume":"14","author":"Jhawar","year":"2022","journal-title":"Cancers"},{"key":"R9-20250608","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ccell.2017.01.001","article-title":"Comprehensive molecular characterization of pheochromocytoma and paraganglioma","volume":"31","author":"Fishbein","year":"2017","journal-title":"Cancer Cell"},{"key":"R10-20250608","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nrc3648","article-title":"Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity","volume":"14","author":"Dahia","year":"2014","journal-title":"Nat Cancer"},{"key":"R11-20250608","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrendo.2014.188","article-title":"Paraganglioma and phaeochromocytoma: from genetics to personalized medicine","volume":"11","author":"Favier","year":"2015","journal-title":"Nat Rev Endocrinol"},{"key":"R13-20250608","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/gim.2014.147","article-title":"A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment","volume":"17","author":"Hampel","year":"2015","journal-title":"Genet Med"},{"key":"R14-20250608","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: an Endocrine Society Clinical Practice Guideline","volume":"99","author":"Lenders","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"R15-20250608","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/his.13277","article-title":"Succinate dehydrogenase (SDH)-deficient neoplasia","volume":"72","author":"Gill","year":"2018","journal-title":"Histopathology"},{"key":"R16-20250608","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.gim.2021.08.004","article-title":"Quantifying evidence toward pathogenicity for rare phenotypes: the case of succinate dehydrogenase genes, SDHB and SDHD","volume":"24","author":"Garrett","year":"2022","journal-title":"Genet Med"},{"key":"R17-20250608","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1200\/JCO.2011.34.6353","article-title":"Metastatic pheochromocytoma\/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations","volume":"29","author":"King","year":"2011","journal-title":"J Clin Oncol"},{"key":"R18-20250608","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.urology.2014.01.007","article-title":"The genetic basis of pheochromocytoma and paraganglioma: implications for management","volume":"83","author":"Shuch","year":"2014","journal-title":"Urology"},{"key":"R19-20250608","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/PAT.0b013e3283539932","article-title":"Succinate dehydrogenase (SDH) and mitochondrial driven neoplasia","volume":"44","author":"Gill","year":"2012","journal-title":"Pathology"},{"key":"R20-20250608","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/s41379-021-00998-1","article-title":"Expanding the clinicopathological spectrum of succinate dehydrogenase-deficient renal cell carcinoma with a focus on variant morphologies: a study of 62 new tumors in 59 patients","volume":"35","author":"Fuchs","year":"2022","journal-title":"Mod Pathol"},{"key":"R21-20250608","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1097\/PAS.0000000000000617","article-title":"Fumarate hydratase deficient renal cell carcinoma is strongly correlated with fumarate hydratase mutation and hereditary leiomyomatosis and renal cell carcinoma syndrome","volume":"40","author":"Trpkov","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"R22-20250608","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/PAS.0000000000001372","article-title":"A clinicopathologic and molecular analysis of fumarate hydratase-deficient renal cell carcinoma in 32 patients","volume":"44","author":"Lau","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"R23-20250608","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/PAS.0000000000000573","article-title":"Fumarate hydratase deficient uterine leiomyomas occur in both the syndromic and sporadic settings","volume":"40","author":"Harrison","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"R24-20250608","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1038\/s41379-021-00779-w","article-title":"New developments in existing WHO entities and evolving molecular concepts: the Genitourinary Pathology Society (GUPS) Update on Renal Neoplasia","volume":"34","author":"Trpkov","year":"2021","journal-title":"Mod Pathol"},{"key":"R25-20250608","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1093\/hmg\/ddt639","article-title":"Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas","volume":"23","author":"Castro-Vega","year":"2014","journal-title":"Hum Mol Genet"},{"key":"R26-20250608","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.ccr.2013.04.018","article-title":"SDH mutations establish a hypermethylator phenotype in paraganglioma","volume":"23","author":"Letouz\u00e9","year":"2013","journal-title":"Cancer Cell"},{"key":"R27-20250608","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/cge.13014","article-title":"Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French FH mutation carriers","volume":"92","author":"Muller","year":"2017","journal-title":"Clin Genet"},{"key":"R28-20250608","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1038\/s41379-020-0596-y","article-title":"Targeted sequencing of FH-deficient uterine leiomyomas reveals biallelic inactivating somatic fumarase variants and allows characterization of missense variants","volume":"33","author":"Popp","year":"2020","journal-title":"Mod Pathol"},{"key":"R29-20250608","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s12022-018-9534-7","article-title":"Old, new, and emerging immunohistochemical markers in pheochromocytoma and paraganglioma","volume":"29","author":"Cheung","year":"2018","journal-title":"Endocr Pathol"},{"key":"R30-20250608","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.humpath.2017.10.013","article-title":"The utility of SDHB and FH immunohistochemistry in patients evaluated for hereditary paraganglioma\/pheochromocytoma syndromes","volume":"71","author":"Udager","year":"2018","journal-title":"Hum Pathol"},{"key":"R31-20250608","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1097\/PAS.0000000000001415","article-title":"Morphological clues to succinate dehydrogenase (SDH) deficiency in pheochromocytomas and paragangliomas","volume":"44","author":"Turchini","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"R32-20250608","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000345668","article-title":"von Hippel-Lindau syndrome","volume":"41","author":"Chou","year":"2013","journal-title":"Front Horm Res"},{"key":"R33-20250608","first-page":"45","article-title":"Utility of the succinate:fumarate ratio for assessing SDH dysfunction in different tumor types","volume":"10","author":"Kim","year":"2017","journal-title":"Mol Genet Metab Rep"},{"key":"R34-20250608","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/s41436-018-0106-5","article-title":"Metabolome-guided genomics to identify pathogenic variants in isocitrate dehydrogenase, fumarate hydratase, and succinate dehydrogenase genes in pheochromocytoma and paraganglioma","volume":"21","author":"Richter","year":"2019","journal-title":"Genet Med"},{"key":"R35-20250608","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/humu.23900","article-title":"Fumarate hydratase FH c.1431_1433dupAAA (p.Lys477dup) variant is not associated with cancer including renal cell carcinoma","volume":"41","author":"Zhang","year":"2020","journal-title":"Hum Mutat"},{"key":"R36-20250608","doi-asserted-by":"crossref","first-page":"E2046","DOI":"10.1210\/jc.2014-1659","article-title":"Germline FH mutations presenting with pheochromocytoma","volume":"99","author":"Clark","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"R37-20250608","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ajhg.2018.04.013","article-title":"Comprehensive Cancer-predisposition gene testing in an adult multiple primary tumor series shows a broad range of deleterious variants and atypical tumor phenotypes","volume":"103","author":"Whitworth","year":"2018","journal-title":"Am J Hum Genet"},{"key":"R38-20250608","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1097\/PGP.0000000000000091","article-title":"Current morphologic criteria perform poorly in identifying hereditary leiomyomatosis and renal cell carcinoma syndrome-associated uterine leiomyomas","volume":"33","author":"Alsolami","year":"2014","journal-title":"Int J Gynecol Pathol"},{"key":"R39-20250608","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1038\/modpathol.2013.215","article-title":"Uterine smooth muscle tumors with features suggesting fumarate hydratase aberration: detailed morphologic analysis and correlation with S-(2-succino)-cysteine immunohistochemistry","volume":"27","author":"Reyes","year":"2014","journal-title":"Mod Pathol"},{"key":"R40-20250608","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/PAS.0000000000000163","article-title":"Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cancer: recognition of the syndrome by pathologic features and the utility of detecting aberrant succination by immunohistochemistry","volume":"38","author":"Chen","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"R41-20250608","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00428-015-1783-y","article-title":"Genetic testing of leiomyoma tissue in women younger than 30 years old might provide an effective screening approach for the hereditary leiomyomatosis and renal cell cancer syndrome (HLRCC)","volume":"467","author":"Martinek","year":"2015","journal-title":"Virchows Arch"},{"key":"R42-20250608","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1136\/jmedgenet-2018-105427","article-title":"Bayesian approach to determining penetrance of pathogenic SDH variants","volume":"55","author":"Benn","year":"2018","journal-title":"J Med Genet"},{"key":"R43-20250608","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s12672-012-0113-y","article-title":"Somatic mutation analysis of the SDHB, SDHC, SDHD, and RET genes in the clinical assessment of sporadic and hereditary pheochromocytoma","volume":"3","author":"Weber","year":"2012","journal-title":"Horm Cancer"},{"key":"R44-20250608","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/cen.14289","article-title":"A review of the tumour spectrum of germline succinate dehydrogenase gene mutations: beyond phaeochromocytoma and paraganglioma","volume":"93","author":"MacFarlane","year":"2020","journal-title":"Clin Endocrinol"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001945","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T17:02:24Z","timestamp":1749402144000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,22]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000001945","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.742288693.793597447","asserted-by":"object"}]},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8,22]]}}}